GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Intech Biopharm 6461.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

26.15

-2.06%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Intech Biopharm

Its shares trade on Taipei Exchange under the ticker 6461.TWO. It has been listed since 15 July 2014. In the fiscal year to 31 December 2025, it reported revenue of TWD 107.5m and a net loss of TWD 389.0m. At that date it held total assets of TWD 2.35bn and shareholders' equity of TWD 1.10bn.

Intech Biopharm Ltd. engages in the development of drugs for obstructive airway diseases such as bronchial asthma and chronic obstructive pulmonary disease. The company is headquartered in Taipei City, Taipei. The company went IPO on 2014-07-15. The firm's main products include respiratory drugs, the Duasma hexafluoroacetone (HFA) metered-dose inhalers (MDIs) and the Synvent HFA MDIs. The firm distributes its products in domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
15 Jul 2014

Leadership

Pay as last reported

  • Mr. Chih-Hui LinChairman of the Board, since 2010
  • Mr. Manish ChawlaGeneral Manager
  • Mr. Guoxiong WuDeputy General Manager
  • Shuhui ChenSenior Manager of Accounting, Corporate Governance Officer
  • Mr. Teh-Chien ChouDirector
  • Mr. Chi-Ying HuangDirector
  • Qirui LiDirector
  • You-Li LiaoDirector
  • Yumei XueDirector
  • Ms. Fangping ChenIndependent Director
  • Mr. Dequan FanIndependent Director
  • Ms. Xiumei LinIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Taipei City, Taipei
  • Develops drugs for obstructive airway diseases including bronchial asthma and COPD
  • Offers respiratory drugs such as Duasma HFA MDIs and Synvent HFA MDIs

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • No details on financial performance or market share provided
  • No information on R&D capabilities beyond product development

Opportunities

  • Expanding distribution to overseas markets
  • Growing demand for respiratory drugs in domestic and international markets
  • Potential for product line expansion in respiratory disease treatment

Threats

  • Dependence on a limited product portfolio including Duasma and Synvent MDIs
  • Competition in the pharmaceutical industry for respiratory drugs
  • Regulatory challenges in drug development and distribution

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.